Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1003877 | 0.87 | MEN1 (0.46) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1002029 | 0.83 | CHRM2 (0.42) | KMT2AALDH1A1LMNASMN1; SMN2HTT | |
| Trifluoroacetic Acid SCHEMBL28004748 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1000673 | 0.80 | KMT2A (0.63) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1000750 | 0.79 | SMN1; SMN2 (0.50) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1000490 | 0.79 | MEN1 (0.51) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1000772 | 0.77 | KMT2A (0.48) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1002014 | 0.77 | KMT2A (0.53) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1001582 | 0.74 | KMT2A (0.80) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1000747 | 0.73 | KMT2A (0.64) | MEN1KMT2AALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | MEN1 4600/4885KMT2A 473/4885ALDH1A1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.